These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3226562)

  • 1. [Antihypertensive efficacy and effects on intra and extracellular electrolytes of a canrenoate potassium-butizide combination].
    Costa FV; Borghi C; Mussi A; Ambrosioni E
    Minerva Cardioangiol; 1988 Oct; 36(10):503-7. PubMed ID: 3226562
    [No Abstract]   [Full Text] [Related]  

  • 2. [Potassium canrenoate and the combination of potassium canrenoate-butizide in the therapy of light to moderate arterial hypertension].
    Morabito S; Fabiano M; Puliti M; Palumbo R; Marinelli R; Simonetti BM; Pierucci A
    Clin Ter; 1992 Jul; 141(7):23-8. PubMed ID: 1505173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interference of canrenoate potassium with plasma renin activity. Note I. Effects of canrenoate potassiumon plasma renin activity in patients with essential hypertension].
    Consolo F; Ferraù O; Pitrone F; Luzza G; Russo A; Virga T
    Boll Soc Ital Biol Sper; 1975 Dec; 51(24):1943-9. PubMed ID: 1231877
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of canrenoate potassium given orally in ascitogenic cirrhosis].
    Sarti F; Milandri GL; Piemontese A; Macchia S; Simoni S; Dal Monte PR
    Minerva Dietol Gastroenterol; 1984; 30(3):273-80. PubMed ID: 6504377
    [No Abstract]   [Full Text] [Related]  

  • 5. [Efficacy of canrenoate potassium in hypertensive cardiopathy. Clinical and echocardiographic evaluation].
    Caporicci D; Achilli L
    Minerva Cardioangiol; 1984 Sep; 32(9):581-7. PubMed ID: 6514202
    [No Abstract]   [Full Text] [Related]  

  • 6. [A new approach to the therapy of hypertensive states].
    Pesa O; Di Tommaso C; Lalli P; Gianmichele M; De Francesco G; Staniscia G; Gasbarrini G
    Minerva Cardioangiol; 1979 Nov; 27(11):667-70. PubMed ID: 44548
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of potassium canrenoate on arterial pressure, plasma renin activity and urinary aldosterone in essential hypertension].
    Opocher G; Armanini D; Fallo F; Mantero F
    Boll Soc Ital Cardiol; 1978; 23(10):1757-66. PubMed ID: 400390
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of canrenoate potassium on intraoperative disturbances of electrolyte equilibrium].
    Eschner J; Fodor L; Ahnefeld FW
    Infusionsther Klin Ernahr; 1976 Apr; 3(2):98-104. PubMed ID: 965083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Essential arterial hypertension. A therapeutic proposal].
    Di Veroli C; Iugoli AR
    Arch Sci Med (Torino); 1981; 138(3):355-60. PubMed ID: 6119065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive and hypokalemic effects of isobutyl hydrochlorothiazide alone and in combination with spironolactone.
    Lochaya S; Suvachittanont O; Triyanond K
    J Med Assoc Thai; 1985 Aug; 68(8):399-407. PubMed ID: 3906011
    [No Abstract]   [Full Text] [Related]  

  • 11. [Value of potassium canrenoate in the prevention of arrhythmia during the acute phase of myocardial infarction].
    Denis B; Machecourt J; Denis MC; Morena H; Pellet J; Rossignol B; Martin-Noël P
    Arch Mal Coeur Vaiss; 1979 Sep; 72(9):1014-22. PubMed ID: 116612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [False values of blood digoxin in patients with acute and chronic liver disease. Role of canrenoate potassium and comparison of radioimmunologic and immunoenzymatic methods].
    Nardoni A; di Piazza V; Moretti V; Copetti R; Trinco G; Geatti O
    Clin Ter; 1988 May; 125(4):287-90. PubMed ID: 2974364
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of spironolactone and K-canrenoate in ascitic cirrhosis. Double-blind study].
    Tempini S; Bellati G; Ideo G
    Minerva Dietol Gastroenterol; 1984; 30(3):255-61. PubMed ID: 6504374
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapeutic report on an injectable aldosterone antagonist (K-canrenoate) in states of water-salf retention].
    Coltorti M; Radaeli E; Ciaccio S; Corsini R; Trebbi R
    Clin Ter; 1976 Feb; 76(3):215-34. PubMed ID: 963962
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of digitalis toxicity with intravenous potassium canrenoate.
    Gavrilescu G; Cristodorescu R; Deutsch G; Berger E
    Agressologie; 1977; 18(3):167-71. PubMed ID: 920909
    [No Abstract]   [Full Text] [Related]  

  • 16. [Use of potassium canrenoate in cardiosurgery].
    Tufano R; Scopa M; Brando G; Leone D
    Minerva Anestesiol; 1981 Apr; 47(4):149-54. PubMed ID: 7242963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites].
    Traina M; Vizzini GB
    Minerva Med; 1986 Jan; 77(3-4):87-91. PubMed ID: 3511409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M; Cuppone R; Ricci GL
    Arzneimittelforschung; 1988 Oct; 38(10):1492-5. PubMed ID: 3058132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of Soludactone in cardiac surgery in adults].
    Fogliani J; Capuccio P; Goudard A; Guillen JC; Monties JR
    Ann Anesthesiol Fr; 1975; 16(3):189-96. PubMed ID: 241276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic effect of canrenoate potassium (soldactone) in patients after open-heart surgery].
    Matsuda K; Tatsuta N; Konishi Y; Minami K; Nishiwaki N; Yamasato A; Chiba Y; Ishihara H; Murata S; Shiraishi Y; Muraguchi T; Hikasa Y
    Nihon Geka Hokan; 1982 May; 51(3):519-27. PubMed ID: 7138201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.